China's Growing Pharmaceutical Dominance Raises Concerns Over Global Supply Chain Dependence and Drug Quality

Photo: IANS

New Delhi: China's expanding influence in global pharmaceutical manufacturing, particularly in the production of active pharmaceutical ingredients (APIs) and essential medical supplies, is raising concerns over supply-chain vulnerabilities and the growing dependence of other countries on a single source, a report has said.

The concerns extend beyond supply-chain resilience to quality control and regulatory compliance. Recent inspections at some Chinese manufacturing facilities have reportedly identified shortcomings in documentation, manufacturing practices and quality assurance systems, according to a report by Maldives Insight.

The report, however, noted that such findings should not be generalised to the entire Chinese pharmaceutical industry. Instead, they highlight the difficulties regulators face in overseeing complex international supply chains involving multiple countries and thousands of manufacturing facilities.

China has emerged as one of the world's largest producers of APIs, supplying thousands of essential ingredients used in medicines marketed across North America, Europe and Asia. Its position has been strengthened by government support, large-scale industrial clusters and relatively low production costs.

The report also highlighted concerns surrounding the growing global demand for GLP-1 drugs, which are widely used in the treatment of diabetes and obesity. The increasing reliance on Chinese pharmaceutical manufacturing for such products has brought the issue of supply-chain concentration into sharper focus.

While China's expanding pharmaceutical sector is often viewed as an example of industrial growth and economic opportunity, critics argue that its strategic implications go beyond commercial interests. They contend that Beijing's growing role in pharmaceutical manufacturing could create long-term dependence among countries relying on Chinese suppliers.

Pharmaceuticals, biotechnology and healthcare innovation form important pillars of China's long-term industrial strategy. The sector also has broader implications for Beijing's influence in areas closely linked to public health and national security.

Highlighting the complexity of modern pharmaceutical supply chains, the report noted that a medicine could be developed by a company in the United States, tested in Europe, manufactured in Asia and distributed across global markets. Any disruption at a critical stage could therefore trigger shortages affecting millions of patients.

The Covid-19 pandemic exposed these vulnerabilities, prompting policymakers in the United States, Europe, Japan and several other countries to push for greater domestic pharmaceutical manufacturing capacity and diversification of suppliers for essential medicines.

Concerns have also periodically emerged over the quality of certain Chinese-manufactured APIs and medical devices exported to international markets, with some manufacturers reportedly falling short of established production standards.

The growing debate highlights the need for stronger regulatory oversight, diversified sourcing and more resilient pharmaceutical supply chains to ensure uninterrupted access to safe and quality medicines worldwide.